Results 211 to 220 of about 14,163 (275)
ESC Heart Failure, Volume 12, Issue 3, Page 1942-1955, June 2025.Abstract Aims Patients with cardiomyopathies are a heterogeneous group of patients who experience high morbidity and mortality. Early cardiac assessment and intervention with access to genetic counselling in a multidisciplinary Cardiomyopathy Clinic may improve outcomes and prevent progression to advanced heart failure.
Chandu Sadasivan +12 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 3, Page 1965-1976, June 2025.Abstract Background The optimal strategy for modern chemotherapy should be based on a comprehensive approach for cancer patients with cardiovascular diseases. Therefore, cardio‐oncology has received increasing attention owing to the cardiotoxic effects of anti‐cancer therapies.
Tomiko Sunaga +7 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 3, Page 1544-1557, June 2025.Abstract Heart failure with preserved ejection fraction (HFpEF) is defined by heart failure (HF) with a left ventricular ejection fraction (LVEF) of at least 50%. HFpEF has a complex and heterogeneous pathophysiology with multiple co‐morbidities contributing to its presentation. Establishing the diagnosis of HFpEF can be challenging.
Roy Rasalam +4 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 3, Page 1977-1991, June 2025.Abstract Aims The study aims to examine characteristics and outcomes associated with health‐related quality of life (HRQoL) in patients with heart failure (HF) with preserved, mildly reduced and reduced ejection fraction (EF) (HFpEF, HFmrEF and HFrEF). Methods and results Data on HRQoL were collected in the Swedish Heart Failure Registry (SwedeHF; 2000–
Camilla Settergren +6 more
wiley +1 more source
Sacubitril and valsartan fixed combination to reduce heart failure events in post-acute myocardial infarction patients [PDF]
, 2017 Lang, C. C., Zaid Iskandar, M.
core +2 more sources
ESC Heart Failure, Volume 12, Issue 3, Page 2023-2033, June 2025.Abstract Aims Dapagliflozin (DAPA), a sodium‐glucose co‐transporter 2 inhibitor, has been shown to reduce cardiovascular mortality among patients with chronic heart failure. We aimed to evaluate the impact on a worsening renal function (WRF) by adding DAPA as compared to standard decongestive therapy with loop diuretics alone.
Shodai Kawanami +11 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 3, Page 2047-2056, June 2025.Abstract Aims The Tpeak‐Tend interval on electrocardiogram may be a predictor of worse outcomes in Takotsubo syndrome (TTS), but the mechanisms have not been fully determined. This study aimed to investigate the relationships between the corrected Tpeak‐Tend (cTp‐e) interval and coronary microvascular‐dysfunction (CMD) assessed by the angiography ...
Kyohei Onishi +6 more
wiley +1 more source